Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood
Chenyu Lin(Duke University), Anthony D. Sung(Duke University), Rocio Manghani, Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Corey Cutler(Harvard University), Yan Song(Chinese Academy of Medical Sciences & Peking Union Medical College), James Signorovitch(Analysis Group (United States)), Claudio G. Brunstein(Hotel Dieu Hospital), Qing Liu(Analysis Group (United States)), Gautam Sajeev(Analysis Group (United States)), Rabi Hanna(Cleveland Clinic), Caroline A. Lindemans(University Medical Center Utrecht), Guillermo Sanz(Instituto de Salud Carlos III), Andrew R. Rezvani(Stanford Blood Center), Smitha Sivaraman, Liang Piu Koh(National University Cancer Institute, Singapore), William Ying Khee Hwang(Singapore General Hospital), Richard T. Maziarz(Oregon Health & Science University), Patrick J. Stiff(Loyola University Medical Center)
Cited by 12
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k